Pre-Conference Workshop

 

Wednesday 15th May 2019

 

09:00 - 10:00

Using CRISPR for preclinical drug discovery 
Danilo Maddalo, Lab Head, Oncology Pharmacology, Novartis Institutes for BioMedical Research

In vivo genome and base editing treatments of a human PCSK9 knock-in hypercholesterolemic mouse model 

  • Generation of humanized hypercholesterolemic in vivo model 
  • Understanding off-target effect of genome and base editing in vivo 

Marcello Maresca, Associate Director, Discovery Sciences, AstraZeneca 

Precise genome engineering to empower drug discovery 
Barry Rosen, Senior Principal Scientist/Director, AstraZenca

 

Process Considerations for Cryogenic and Regenerative Medicine Commercialization 
HOSTED BY cryoport

 

Welcome remarks: Mark Sawicki, Chief Commercial Officer, Cryoport
Panel Discussion: Integration and Data Continuity Throughout the Regenerative Medicine Production Process 
Be The Match BioTherapies Representative
GE Healthcare Representative
TrakCel Representative
Atara Representative
Orchard Therapeutics Representative

 

 

Workshop room A

Manufacture and bioprocess of CAR-T 
Moderator: Qasim Rafiq, Senior Lecturer (Associate Professor), Bioprocessing of Regenerative, Cellular and Gene Therapies, Department of Biochemical Engineering, UCL 

 

Workshop room B

Seeking investment summit – Organized by ISCT Business Models & Investment Subcommittee
Strengthening ties between the science and commercial: From investor to investigator 
Connecting investigators with investors

Bill Milligan, Co-Chair, Steminent Biotherapeutics Inc.
Suzanne Farid, Professor of Bioprocess Systems Engineering, University College London 
Matthew Durdy, CBO, Cell and Gene Therapy Catapult 

Workshop room C

Focus group: To advance process, measurement, and analytical techniques of regenerative medicine products and services 
Moderator: Sven Kili, Head of Cell & Gene Therapy Development, GSK 

 

Networking break
 
11:00 - 12:00

 

Panel discussion: Systems compliance and traceability during product distribution
Cryoport Representative 
World Courier Representative 

Using imaging to improve the success rate of CAR-T therapies on solid tumors 
Host: David Morrow, Programme Manager, EATRIS

Focus group: To advance process, measurement, and analytical techniques of regenerative medicine products and services 
Moderator: Sven Kili, Head of Cell & Gene Therapy Development, GSK 

 

 

Synthetic biology for cell and gene therapies presentations followed by panel discussion 

  • Moving from autologous to allogenic function 
  • Where are we really headed?

Bob Deans, CTO, BlueRock Therapeutics
Jim Collins, Termeer Professor of Bioengineering in the Department of Biological Engineering and Institute for Medical Engineering & Science, MIT
Peter Zandstra, Professor & Director, Michael Smith Laboratories, University of British Columbia / Professor, University of Toronto Synbio Canada
Potential sponsor Sentibio

 

Networking lunch


13:00 - 14:20

Panel discussion: Regenerative medicine globalization; considerations for effective launch activity beyond your initial geographic launch
Alain Vertès, VP Alliance Management, Mesoblast
Be The Match Representative
Cryoport Representative
Bruce Phelan, Consultant, Blue Fin Group
World Courier Representative 
Gilead Representative
CBMG Representative 

Using machine learning and analytical tools to expand on cellular function and gene editing 
The cell is the fundamental unit of life. We use diverse technologies and approaches at a large scale in order to study complex cells as integrated systems and propel biomedical research forward. 
Learn: hiPSC cell lines that allow for imaging of live cells, and the associated data, tools and applications 
Rick Horwitz, Executive Director, Allen Institute

Researcher and academic masterclass in manufacture and bioprocessing – Part 1
QbD PAT Scale up + scale down cultivation strategies, process development, and downstream
Case studies transferring manufacturing and bioprocessing systems into industry
Oliver Spadiut, Integrated Bioprocess Development, Chemical Engineering, TU Wien
David Wurm, Group Integrated Bioprocess Development, Vienna University of Technology 

 

Networking break
 
15:00 - 17:00

 

Closing keynote panel: Advances in Genome Editing – The Next Frontier in Human Health 
  • Knockout and repair applications 
  • Potential applications 
  • Tackling immunogenicity 
  • Off target effects and improving efficacy 
  • Being vigilant with safety profiles  
  • Potency and manufacturing 
  • Solid tumor environment 
  • Moving towards direct, in vivo (live delivery using nanoparticles) 
  • Viral and non-viral (lipid nanoparticles)
Lakiea Bailey, Executive Director. WWBD, Sickle Cell Community Consortium
Katrine Bosley, CEO, Editas Medicine
Mike Certo, Head, Genome Editing, bluebird bio
Samarth Kulkarni, Chief Executive Officer, Crispr Therapeutics 

Scalability (30 Min Sessions)

  • Systems (GE, Agilent)
  • Data (Be The Match, Trakcel)
  • Infrastructure (World Courier, Cryoport, Hitatchi)
  • Infrastructure (World Courier, Cryoport, Hitatchi)

Agilent Representative
GE Healthcare Representative
Be The Match BioTherapies Representative
TrakCel Representative
Bob Preti, CEO, Hitachi
Cryoport Representative
World Courier Representative

Clinical trial focus workshop: What needs to be done to get these experimental treatments to patients in the clinic?

  • Centralized and decentralized models
  • Sourcing starting material: apheresis, tumor, bone marrow
  • From manufacture to back into local environment
  • Design of clinical trial 

Chair: Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult 

 

 

Researcher and academic masterclass in manufacture and bioprocessing – Part 2
QbD PAT Scale up + scale down cultivation strategies, process development, and downstream
Case studies transferring manufacturing and bioprocessing systems into industry
Oliver Spadiut, Integrated Bioprocess Development, Chemical Engineering, TU Wien
David Wurm, Group Integrated Bioprocess Development, Vienna University of Technology

Workshop: Automating CAR-T manufacturing, a step by step guide
Rodney L Rietze, Director, Strategic Development and Innovation, Cell and Gene Therapy Development and Manufacturing, Novartis 

 

 

17:30 End of Pre-conference day followed by opening networking drinks 

 

 

DOWNLOAD PROSPECTUS

 

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com